Skip to content
    AMRX
    Earnings call· Jun 2026(Q2 FY26)

    Amneal Pharmaceuticals Q2 FY26 earnings call AMRX

    Jul 30, 2026 Source

    Executive summary

    Amneal Q2 FY26 — Strong Performance, Raised Outlook, and Strategic Transformation

    Amneal Pharmaceuticals delivered strong Q2 FY26 results, driven by momentum in Affordable Medicines and Specialty segments, leading to a raised full-year outlook. The company is undergoing a transformative period, focusing on biosimilars through the Kashiv acquisition, expanding its complex generics portfolio, and advancing its Specialty pipeline, including a GLP-1 partnership, to become a leader in affordable and essential medicines.

    Highlights

    5

    • Total net revenue grew 10% year-over-year to $796 million.

    • Adjusted EBITDA increased 12% year-over-year to $206 million.

    • Adjusted EPS rose 20% year-over-year to $0.30.

    • Full-year 2026 revenue outlook raised by $50 million to $3.1 billion - $3.2 billion.

    • Full-year 2026 adjusted EBITDA guidance raised by $10 million to $750 million - $780 million.

    Concerns

    2

    • AvKARE revenue decreased 4% year-over-year to $157 million, due to the low-margin distribution business.

    • India facility flood is estimated to have a $20 million negative impact on full-year 2026 guidance.

    Guidance & targets

    14
    CategoryTargetConfidence
    Full-year 2026 Total Net Revenue
    $3.1 billion to $3.2 billion
    high materiality
    High
    Full-year 2026 Adjusted EBITDA
    $750 million to $780 million
    high materiality
    High
    Full-year 2026 Adjusted EPS
    $0.96 to $1.06
    high materiality
    High
    Full-year 2026 Capital Expenditure
    ~$150 million
    medium materiality
    High
    Full-year 2026 Operating Cash Flow
    Maintained
    medium materiality
    High
    Net Leverage Ratio
    Below 3x
    high materiality
    High
    Lanreotide Launch Timing
    Q3 FY26
    high materiality
    High
    XOLAIR Biosimilar Launch Timing
    Very late end of FY26 or early FY27
    high materiality
    Medium
    Kashiv Drug Substance Capacity Expansion
    ~75,000 liters
    medium materiality
    High
    Biosimilar Filings per Year
    3-4 biosimilars a year
    medium materiality
    Medium
    Affordable Medicines New Revenue
    $1 billion to $2 billion
    high materiality
    High
    Estrogen Patch Capacity
    Triple capacity
    medium materiality
    High
    GLP-1 Supply Operational Timing
    2029 and '30
    high materiality
    High
    GLP-1 Supply Start
    2030
    high materiality
    High

    Segment performance

    3
    SegmentRevenueYoYQoQMargin
    Affordable Medicines
    Reflecting the strength of the broad-based complex portfolio, including Women's Health products, injectables, and higher naloxone sales.
    New product launches contribution to Q2 revenue: $45 million
    		$490 million13%——
    Specialty
    Driven by continued momentum in CREXONT, UNITHROID, and BREKIYA, all ahead of expectations.
    		$149 million17%——
    AvKARE
    Growth in the government channel was offset by the low-margin distribution business.
    		$157 million-4%——

    Operational metrics

    16
    Total Net Revenue
    $796 millionup 10%
    Q2 FY26

    Company-wide revenue.

    Adjusted EBITDA
    $206 millionup 12%
    Q2 FY26

    Company-wide adjusted EBITDA.

    Adjusted EPS
    $0.30up 20%
    Q2 FY26

    Company-wide adjusted EPS.

    Adjusted Gross Margin
    46.2%up 60 basis points year-over-year
    Q2 FY26

    Strong gross margin performance.

    First Half Total Revenue Growth
    7%
    H1 FY26

    First half financial performance.

    First Half Adjusted EBITDA Growth
    16%
    H1 FY26

    First half financial performance.

    First Half Adjusted EPS Growth
    27%
    H1 FY26

    First half financial performance.

    Term Loan B Interest Expense Savings
    $12 million
    Annual

    Result of repricing $2.084 billion Term Loan B due 2032.

    Kashiv Financial Benefits
    $400 million to $500 million
    Long-term

    Expected financial benefits from the Kashiv acquisition.

    New Product Launches Contribution to Revenue
    $45 million
    Q2 FY26

    Contribution from two recently launched products in ophthalmology and urology.

    CREXONT Scripts from General Neurologists
    80%
    Current

    Indicates broader adoption compared to RYTARY.

    Iohexol Market Opportunity
    $50+ million
    Annual

    Potential market opportunity for the complex product.

    Biosimilar Programs in Pipeline
    Over 20
    Ongoing

    Combined pipeline with Kashiv.

    Biosimilar Portfolio Focus
    75%
    Ongoing

    Remaining 25% addresses larger market opportunities.

    Biologics Losing Exclusivity in US
    118
    Next decade

    Driving major growth cycle in US biosimilars market.

    High-Value Complex ANDA Filings Planned
    12 to 15
    FY26

    Reflects continued innovation in the Affordable Medicines pipeline.

    Industry KPIs

    8
    MetricValueDetails
    EPS revenue guidanceRevenue: $3.1B-$3.2B; Adj. EBITDA: $750M-$780M; Adj. EPS: $0.96-$1.06USD
    Pricing policy impactTariffs
    Pipeline clinical milestones12 to 15filings
    Regulatory approvals filingsLanreotide
    Therapeutic drug market share80%%
    Glp 1 incretin franchise metricsPfizer partnership
    Clinical trial efficacy safety data3 or more hourshours
    Business development capacity deal appetiteCNS and oncology assets

    Deals & partnerships

    2
    Kashiv BioSciencesAcquisition to build a fully integrated global biosimilar platform, spanning development to commercial supply.

    Adds in-house biologics capabilities, including cell line and clone development, protein characterization, process development, clinical execution, regulatory expertise, and scaled biologics manufacturing in India and U.S. Expected to close pending shareholder vote and closing conditions.

    PfizerPartnership for GLP-1 peptides.

    Partnership is moving extremely well, with plans to expand. Both manufacturing plants are expected to be operational in 2029 and 2030, with supply starting in 2030. Exclusive commercial rights in markets like India and Egypt are looking good.

    Risks & headwinds

    2
    India facility flood impactFull-year 2026

    $20 million negative impact

    Mitigation: Expect to resume operation within the next few weeks; limited impact on select products.

    AvKARE low-margin distribution businessQ2 FY26

    Revenue down 4% year-over-year

    Mitigation: Company remains focused on the unique value in the government channel and expanding profitability.

    What to watch in Q3 FY26

    5

    Lanreotide Approval and Launch

    Q3 FY26
    CurrentOfficial goal date in Q3 FY26
    TargetApproval and commercial launch

    Why it matters

    This is a high-value, complex generic with significant market potential and high barriers to entry, expected to be a meaningful growth driver.

    So, lanreotide is on its way. That's what we feel as of today. It has official goal date in Q3.

    Q&A highlights

    5

    What is the expected timing for lanreotide and XOLAIR biosimilar launches, and what is included in the H2 FY26 guidance? Can you update on the 6 commercial biosimilars by 2027 and which will be most meaningful?

    Lanreotide is expected in Q3 FY26 with conservative forecast included. XOLAIR biosimilar is late FY26 or early FY27, with no revenue included for this year. The 6 commercial biosimilars by 2027 include existing ALYMSYS, RELEUKO, FYLNETRA, plus upcoming Prolia, XGEVA, and XOLAIR.

    “So, lanreotide is on its way. That's what we feel as of today. It has official goal date in Q3. So that we have included some of the forecast number, but not probably the market... And XOLAIR is towards very late end of the year or could spill into the January 5. So nothing is included for XOLAIR for this year.”

    asked by Glen Santangelo · answered by Chirag Patel

    2 min read6 chapters

    Detailed Narrative

    01

    Strategic Transformation and Growth Drivers

    Amneal is undergoing a significant transformative period, aiming to become a leading provider of affordable medicines. The company is focused on diversifying its portfolio across Specialty brands, biosimilars, GLP-1s, and complex generics. This strategy leverages Amneal's strong R&D, manufacturing, and commercial capabilities to expand patient access and affordability, driving sustained momentum and growth.

    02

    Biosimilars Platform Expansion with Kashiv Acquisition

    The pending acquisition of Kashiv is a cornerstone of Amneal's strategy to build a fully integrated global biosimilar platform. This integration will provide end-to-end capabilities from cell line development to commercial supply, positioning Amneal to capitalize on the upcoming wave of biologics losing exclusivity. The combined pipeline includes over 20 biosimilar programs, with significant opportunities identified for XOLAIR, ORENCIA, CIMZIA, and Nplate.

    03

    Affordable Medicines Momentum and Pipeline

    Amneal's base Affordable Medicines business demonstrates strong resilience and growth, driven by high demand for transdermal patches, including Women's Health products and lidocaine, and injectables. The company's pipeline is concentrated on high-value, complex generics such as lanreotide and iohexol. Amneal plans 12-15 high-value complex ANDA filings this year, including metered-dose inhalation products, reflecting a deliberate strategy to prioritize technically challenging dosage forms.

    04

    Specialty Portfolio Performance and Future Expansion

    The Specialty segment continues its strong performance, with CREXONT for Parkinson's disease gaining significant traction, supported by compelling Phase IV data. BREKIYA is also experiencing robust uptake for migraine and cluster headaches. Amneal plans to expand its Specialty pipeline through internal R&D and potential M&A, particularly in CNS and oncology assets, leveraging its established commercial infrastructure.

    05

    Manufacturing and Supply Chain Resilience

    Amneal emphasizes its global, high-quality manufacturing and supply chain capabilities, enhanced by digitization, automation, and AI tools. The company's Brookhaven, NY site was selected for the FDA's PreCheck Pilot Program, acknowledging its robust U.S. manufacturing and efforts to strengthen supply chain resiliency, especially for sterile injectables. This focus ensures reliable, high-quality supply and addresses market needs and drug shortages.

    06

    Financial Performance and Outlook

    The second quarter saw strong financial performance with double-digit growth in revenue, adjusted EBITDA, and adjusted EPS, leading to a raised full-year 2026 outlook. The company successfully repriced its Term Loan B, reducing annual interest expense by $12 million, and is targeting net leverage below 3x by 2028. These financial strengths support strategic investments and continued growth initiatives.

    AI-generated summary of the company’s earnings call. Not investment advice.